Iowa House Bill HF217

Iowa 2025-2026 Regular Session

• Introduced: 2/6/25
• Refer: 2/6/25

Caption

A bill for an act relating to prior authorization requirements for the treatment of cancer.

Summary

House File 217 would prohibit utilization review organizations and health carriers from requiring prior authorization for cancer-related health care services when those services are recommended by a patient’s provider based on National Comprehensive Cancer Network (NCCN) protocols. In practical terms, the bill creates a prior-authorization exemption for certain cancer treatments that align with widely used oncology guidelines. The measure is narrowly focused on cancer care and does not broadly eliminate prior authorization across health insurance. Instead, it targets a specific category of treatment decisions, tying the exemption to provider recommendations grounded in NCCN protocols. The bill was introduced and referred to the House Health and Human Services Committee, with no recorded amendments, committee vote, or floor action in the provided materials.

Impact

If enacted, the bill would amend Iowa Code section 514F.8 to add a new restriction on health carriers and utilization review organizations, limiting their ability to delay or deny cancer treatment through prior authorization. It would affect insurers, managed care entities, and other utilization review organizations operating in Iowa, while benefiting covered persons receiving cancer care and the providers who recommend treatment under NCCN protocols. The bill would likely reduce administrative hurdles and speed access to oncology services for qualifying patients.

Sentiment

The available record suggests generally favorable or at least supportive intent, as reflected by the bill’s bipartisan list of House sponsors and its patient-access focus. No committee testimony or vote history was provided, so there is no direct evidence of opposition or formal support in debate. Based on the text alone, the bill appears framed as a consumer- and patient-protection measure aimed at improving timely cancer treatment.

Contention

The main potential point of contention is the bill’s effect on insurer utilization management, since it limits prior authorization for a defined set of cancer services. Insurers and utilization review organizations may view the mandate as reducing their ability to control costs or ensure medical necessity, while supporters are likely to argue that NCCN-based recommendations should not be delayed by administrative review. Another possible issue is how broadly the NCCN-protocol standard would be applied in practice and whether it could create ambiguity for carriers and providers.